With the recent approval of a specific PIK3CA inhibitor for breast cancer patients whose tumors harbor PIK3CA mutations or have PIK3CA mutations in their ctDNA, the proficiency testing for PIK3CA mutation analysis was initiated both for tissue and LB samples. This evidence concerns the gene PIK3CA and breast cancer.